282 related articles for article (PubMed ID: 38618963)
1. Infantile hemangioma: the common and enigmatic vascular tumor.
Holm A; Mulliken JB; Bischoff J
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618963
[TBL] [Abstract][Full Text] [Related]
2. Infantile hemangioma-mechanism(s) of drug action on a vascular tumor.
Greenberger S; Bischoff J
Cold Spring Harb Perspect Med; 2011 Sep; 1(1):a006460. PubMed ID: 22229118
[TBL] [Abstract][Full Text] [Related]
3. Pigment epithelium-derived factor/vascular endothelial growth factor ratio plays a crucial role in the spontaneous regression of infant hemangioma and in the therapeutic effect of propranolol.
Zhu L; Xie J; Liu Z; Huang Z; Huang M; Yin H; Qi W; Yang Z; Zhou T; Gao G; Zhang J; Yang X
Cancer Sci; 2018 Jun; 109(6):1981-1994. PubMed ID: 29664206
[TBL] [Abstract][Full Text] [Related]
4. Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl-2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment.
Wnęk A; Andrzejewska E; Kobos J; Taran K; Przewratil P
Immunol Lett; 2017 May; 185():27-31. PubMed ID: 28279700
[TBL] [Abstract][Full Text] [Related]
5. Propranolol therapy for infantile hemangioma: our experience.
Zhang L; Wu HW; Yuan W; Zheng JW
Drug Des Devel Ther; 2017; 11():1401-1408. PubMed ID: 28507428
[TBL] [Abstract][Full Text] [Related]
6. Infantile hemangioma: pathogenesis and mechanisms of action of propranolol.
Rotter A; de Oliveira ZNP
J Dtsch Dermatol Ges; 2017 Dec; 15(12):1185-1190. PubMed ID: 29193649
[TBL] [Abstract][Full Text] [Related]
7. Does Oral Propranolol Improve the Final Outcome of All Involuted Infantile Hemangiomas? A Matched Retrospective Comparative Study.
Chang SJ; Chang HF; Qiu Y; Chang L; Jin Y; Lin X
Ann Plast Surg; 2022 Aug; 89(2):214-217. PubMed ID: 35502973
[TBL] [Abstract][Full Text] [Related]
8. Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.
Pan WK; Li P; Guo ZT; Huang Q; Gao Y
Pediatr Blood Cancer; 2015 Aug; 62(8):1414-20. PubMed ID: 25728347
[TBL] [Abstract][Full Text] [Related]
9. Is Infantile Hemangioma a Neuroendocrine Tumor?
Kaulanjan-Checkmodine P; Oucherif S; Prey S; Gontier E; Lacomme S; Loot M; Miljkovic-Licina M; Cario M; Léauté-Labrèze C; Taieb A; Moisan F; Rezvani HR
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563552
[TBL] [Abstract][Full Text] [Related]
10. Medical Management of Infantile Hemangiomas: An Update.
Colmant C; Powell J
Paediatr Drugs; 2022 Jan; 24(1):29-43. PubMed ID: 34677814
[TBL] [Abstract][Full Text] [Related]
11. Skin sequelae in patients with infantile hemangioma: a systematic review.
Li W; Kang J; Bai S; Yuan L; Liu J; Bi Y; Sun J; He Y
Eur J Pediatr; 2023 Feb; 182(2):479-488. PubMed ID: 36434402
[TBL] [Abstract][Full Text] [Related]
12. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action.
Ji Y; Chen S; Xu C; Li L; Xiang B
Br J Dermatol; 2015 Jan; 172(1):24-32. PubMed ID: 25196392
[TBL] [Abstract][Full Text] [Related]
13. Infantile Sacral Region Hemangioma and Combination Treatment with Propranolol and Topical Timolol: Case Review and Reference Review.
Kardasevic M; Dinarevic SM
Med Arch; 2021 Apr; 75(2):158-161. PubMed ID: 34219878
[TBL] [Abstract][Full Text] [Related]
14. A transcription factor is the target of propranolol treatment in infantile hemangioma.
Schrenk S; Boscolo E
J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 35104803
[TBL] [Abstract][Full Text] [Related]
15. β-blocker therapy for infantile hemangioma.
Koh SP; Leadbitter P; Smithers F; Tan ST
Expert Rev Clin Pharmacol; 2020 Aug; 13(8):899-915. PubMed ID: 32662682
[TBL] [Abstract][Full Text] [Related]
16. Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation.
Munabi NC; England RW; Edwards AK; Kitajewski AA; Tan QK; Weinstein A; Kung JE; Wilcox M; Kitajewski JK; Shawber CJ; Wu JK
Stem Cells Transl Med; 2016 Jan; 5(1):45-55. PubMed ID: 26574555
[TBL] [Abstract][Full Text] [Related]
17. [Infantile hemangioma and propranolol: a therapeutic "revolution". Literature review].
Yilmaz L; Dangoisse C; Semaille P
Rev Med Brux; 2013; 34(6):479-84. PubMed ID: 24505868
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor response with propranolol therapy in patients with infantile hemangioma.
Makkeyah SM; Elseedawy ME; Abdel-Kader HM; Mokhtar GM; Ragab IA
Pediatr Hematol Oncol; 2022 Apr; 39(3):215-224. PubMed ID: 34477031
[TBL] [Abstract][Full Text] [Related]
19. Clinical and radiological outcomes of infantile hemangioma treated with oral propranolol: A long-term follow-up study.
Yu Z; Cai R; Chang L; Qiu Y; Chen X; Chen Q; Ma G; Jin Y; Lin X
J Dermatol; 2019 May; 46(5):376-382. PubMed ID: 30916822
[TBL] [Abstract][Full Text] [Related]
20. Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential biomarkers predicting clinical outcomes.
Park M; Jung HL; Shim YJ; Kim HS; Yoon HS; Park SK; Cheuh HW; Lee MJ; Lee JM; Park ES; Lee JH; Lim YJ; Choi YB
Pediatr Res; 2020 Nov; 88(5):749-755. PubMed ID: 32311699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
